Measles, mumps and rubella: control by vaccination
- PMID: 3556777
Measles, mumps and rubella: control by vaccination
Abstract
In 1984, the Health Council of the Netherlands advised that a new vaccination strategy against measles, mumps and rubella (MMR) should be initiated. The use of a combined MMR vaccine, to be given at 14 months and 9 years of age was recommended. An analysis of this strategy based on mathematical models, predicted that rubella and mumps and very probably measles will be eliminated in The Netherlands before 1990. The use of a combined MMR vaccine has a number of logistical and financial advantages over immunization with separate vaccines. Another factor to be considered is of course the mutual interference regarding immune response or immunization reactions. Less obviously, and often not recognised as an important factor, is the possibility of an adverse effect on the incidence of the congenital rubella syndrome (CRS), when vaccine coverage is low or the natural force of infection of rubella is high. Vaccine induced herd immunity can act to the disadvantage of the unvaccinated individuals. Following earlier work we show that certain vaccination programmes could actually increase the incidence of serious cases. At first sight, this may seem inconceivable. Mathematical analysis, however, reveals that this is indeed a real possibility. Implementing a vaccination programme that is not sufficiently intensive to eradicate the infection in the population will ultimately lead to a new steady state in which the force of infection is lower than in the period before the start of the programme. As a consequence those who are not (effectively) vaccinated have a higher chance of contracting the infection at an older age. For many viral infections, the chance of serious complications is greater if the infection is acquired at an older age. Congenital rubella and measles encephalitis are striking examples (with respect to mumps the situation is less clear). When boys and girls are vaccinated around one year of age and MMR vaccine coverage is lower than approximately 50%, the total number of cases with the congenital rubella syndrome can increase in the long term. When the force of infection of rubella before implementing the vaccination programme is high - which may be the case in developing countries - the effect is more pronounced and even a relatively high vaccine uptake of 80-90% may not be sufficient to keep CRS incidence below the level prior to control.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.Dev Biol Stand. 1986;65:37-43. Dev Biol Stand. 1986. PMID: 3556776
-
The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.N Engl J Med. 1994 Nov 24;331(21):1397-402. doi: 10.1056/NEJM199411243312101. N Engl J Med. 1994. PMID: 7969278
-
The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.Dev Biol Stand. 1986;65:45-52. Dev Biol Stand. 1986. PMID: 3104117 Review.
-
[Certain problems with limits of immunity against measles, mumps and rubella].Przegl Epidemiol. 1993;47(1-2):47-53. Przegl Epidemiol. 1993. PMID: 8351387 Polish.
-
[Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].An Esp Pediatr. 1992 Apr;36(4):293-7. An Esp Pediatr. 1992. PMID: 1605414 Review. Spanish.
Cited by
-
Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes.BMC Med. 2020 Jan 14;18(1):11. doi: 10.1186/s12916-019-1471-x. BMC Med. 2020. PMID: 31931789 Free PMC article.
-
Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review.BMJ. 1999 Dec 4;319(7223):1462-7. doi: 10.1136/bmj.319.7223.1462. BMJ. 1999. PMID: 10582926 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials